Macular Degeneration: A Cutting Edge Update on Wet & Dry MD including Latest Treatments & Trials
Date: 6/04/2022 (AEST)
Venue: Live Webinar- Online Delivery
Provider: Strathfield Retina Clinic
Contact: James Wong, [E] rachelle.lupingna@strathfieldretina.com.au, [P] (02) 9746 3378
Learning Objectives
- Identify characteristics of Geographic Atrophy and higher risk dry macular degeneration phenotypes
- Understand recent trial data about future treatments for Non-neovascular Macular Degeneration
- Identify subtypes of Neovascular Macular Degeneration including Polypoidal Choroidal Vasculopathy
- Understand treatment options for Neovascular MD subtypes
- Understand new trial options and data for Neovascular MD
- Understand Real World Evidence based guidance for treatment of Neovascular MD
Max CPD hours awarded: 1.75
Session Information
| Name |
|---|
| Geographic Atrophy, High Risk Dry MD Phenotypes & New Treatments |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.5 |
| Name |
|---|
| Subtypes of Wet MD: Do we really need to identify them? New Treatment & Trials |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.75 |
| Name |
|---|
| Real-World Guidance of Wet MD: What we should learn |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.25 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 0.5 |